Robert Malenka Sells 2,195 Shares of Maplight Therapeutics (NASDAQ:MPLT) Stock

Maplight Therapeutics, Inc. (NASDAQ:MPLT) Director Robert Malenka sold 2,195 shares of the company’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $18.03, for a total transaction of $39,575.85. Following the completion of the sale, the director directly owned 337,059 shares of the company’s stock, valued at $6,077,173.77. This trade represents a 0.65% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Maplight Therapeutics Stock Down 1.5%

Shares of MPLT stock traded down $0.28 on Tuesday, hitting $18.02. 97,940 shares of the company’s stock traded hands, compared to its average volume of 185,529. The stock has a market cap of $817.57 million and a PE ratio of -0.48. The firm’s fifty day moving average is $17.83. Maplight Therapeutics, Inc. has a one year low of $12.24 and a one year high of $21.55.

Maplight Therapeutics (NASDAQ:MPLT) last posted its quarterly earnings results on Thursday, December 4th. The company reported ($37.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by ($35.32).

Analyst Upgrades and Downgrades

MPLT has been the topic of a number of analyst reports. Morgan Stanley started coverage on Maplight Therapeutics in a research note on Friday, November 21st. They issued an “overweight” rating and a $34.00 price target on the stock. Zacks Research raised shares of Maplight Therapeutics to a “hold” rating in a research note on Monday, November 24th. Leerink Partners initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They set an “outperform” rating and a $30.00 price target for the company. Stifel Nicolaus initiated coverage on shares of Maplight Therapeutics in a report on Friday, November 21st. They issued a “buy” rating and a $28.00 price target on the stock. Finally, Wall Street Zen raised shares of Maplight Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 20th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $31.00.

Hedge Funds Weigh In On Maplight Therapeutics

A number of institutional investors have recently bought and sold shares of MPLT. Strs Ohio bought a new stake in Maplight Therapeutics during the 4th quarter valued at approximately $53,000. Police & Firemen s Retirement System of New Jersey bought a new position in shares of Maplight Therapeutics in the 4th quarter worth approximately $70,000. New York State Common Retirement Fund purchased a new position in shares of Maplight Therapeutics in the 4th quarter valued at approximately $93,000. MetLife Investment Management LLC bought a new stake in shares of Maplight Therapeutics during the fourth quarter valued at approximately $172,000. Finally, Walleye Capital LLC purchased a new stake in Maplight Therapeutics in the fourth quarter worth $205,000.

About Maplight Therapeutics

We are a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. We were founded by globally recognized leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. Our discovery platform holds the potential to fill this void by identifying neural circuits causally linked to disease and targeting those circuits for therapeutic modulation.